Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
2 drugs in development
By Therapeutic Area
top 1
R&D Momentum
38/100
Pipeline Velocity
6/100
Trial Completion Rate
64/100
Pipeline Concentration
100/100
Pipeline Freshness
78/100
Activity
Last 14 days
A Phase 1, First-in-Human, Open Label, Dose Escalation, Dose Optimization, and Cohort Expansion Study of MGC030 in Participants With Advanced Solid Tumors
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)